Oculis Q2 Loss Narrows to CHF 10M, Cash Runway Extended to 2029
OCS sits 18% above its 52-week low of $10.52 on light trading volume (0.4× avg).
Summary
Oculis reported a Q2 net loss of CHF 9.97 million, narrower than expected, driven by a fair value gain on warrant liabilities and favorable currency movements. Operating expenses rose to CHF 23.88 million on higher headcount and share-based compensation to support clinical programs. The company ended the quarter with CHF 228.3 million in cash, providing runway into the second half of 2029. Key pipeline updates: topline results from the Licaminlimab PREDICT-1 trial are expected around year-end, and an IND submission for Privosegtor in acute MS relapses is planned for Q4 2026. Oculis will not pursue an FDA filing for OCS-01 in DME following the Phase 3 failure in May. This follows the May 29 trial miss and subsequent shareholder investigation, but the extended cash runway and new regulatory milestones provide a clearer path forward.
At the time of this announcement, OCS was trading at $12.38 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $707.8M. The 52-week trading range was $10.52 to $34.48. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Reuters.